Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)
Previous Close
$407.09
52W Range
$200.63 - $419.99
50D Avg
$321.29
200D Avg
$317.74
Market Cap
$9.24B
Avg Vol (3M)
$372.49K
Beta
-1.03
Div Yield
-
MDGL Company Profile
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.